Circulation, Vol 81, 1974-1980, Copyright © 1990 by American Heart Association
C Bode, MS Runge, S Schonermark, T Eberle, JB Newell, W Kubler and E Haber
Single-chain urokinase plasminogen activator (scu-PA) that had been
modified with N-succinimidyl-3-(2-pyridyldithio)propionate was covalently
linked by disulfide bonds to the Fab' of a monoclonal antibody specific for
the beta-chain of fibrin (antibody 59D8). scu-PA- 59D8 Fab' conjugate was
separated from free scu-PA and two-chain urokinase coupled to 59D8 Fab' by
two-step affinity chromatography. First, the reaction mixture was
chromatographed on a column containing Sepharose linked to the peptide that
had been used as immunogen for antibody 59D8; scu-PA-59D8 Fab' conjugate
and unconjugated 59D8 Fab' were retained but not unconjugated scu-PA. Then,
the eluate from the peptide-Sepharose column was chromatographed on a
column containing Sepharose linked to benzamidine, which acts as a ligand
for two-chain urokinase. The molecular weight of the scu-PA-59D8 Fab'
conjugate was approximately 100 kDa when electrophoresed on a nonreducing
sodium dodecylsulfate-polyacrylamide gel. Enzymatic assay after
purification revealed that more than 97% of the scu-PA present in the
conjugate retained the single-chain form. The Fab' portion of the conjugate
functioned in a manner indistinguishable from that of native antibody 59D8.
In an in vitro assay for lysis of fibrin monomer, the fibrinolytic potency
of scu-PA-59D8 Fab' was 33-fold more than that of tissue plasminogen
activator (p less than 0.001), 230-fold more than that of unconjugated
scu-PA (p less than 0.0001), and 420-fold more than that of urokinase (p
less than 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)
ARTICLES
Conjugation to antifibrin Fab' enhances fibrinolytic potency of single- chain urokinase plasminogen activator
Medizinische Klinik III (Kardiologie), Universitat Heidelberg, FRG.
This article has been cited by other articles:
![]() |
K. Peter, J. Graeber, S. Kipriyanov, M. Zewe-Welschof, M. S. Runge, W. Kubler, M. Little, and C. Bode Construction and Functional Evaluation of a Single-Chain Antibody Fusion Protein With Fibrin Targeting and Thrombin Inhibition After Activation by Factor Xa Circulation, March 14, 2000; 101(10): 1158 - 1164. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Iqbal, H. Messmore, D. Hoppensteadt, J. Fareed, and W. Wehrmacher State-of-the-Art Review : Thrombolytic Drugs in Acute Myocardial Infarction Clinical and Applied Thrombosis/Hemostasis, January 1, 2000; 6(1): 1 - 13. [PDF] |
||||
![]() |
S. J. Szarka, E. G. Sihota, H. R. Habibi, and S.-L. Wong Staphylokinase as a Plasminogen Activator Component in Recombinant Fusion Proteins Appl. Envir. Microbiol., February 1, 1999; 65(2): 506 - 513. [Abstract] [Full Text] |
||||
![]() |
C. Bode, S. R. Hanson, J. F. Schmedtje, E. Haber, P. Mehwald, A. B. Kelly, L. A. Harker, and M. S. Runge Antithrombotic Potency of Hirudin Is Increased in Nonhuman Primates by Fibrin Targeting Circulation, February 18, 1997; 95(4): 800 - 804. [Abstract] [Full Text] |
||||
![]() |
J. F. Tait, S. Engelhardt, C. Smith, and K. Fujikawa Prourokinase-Annexin V Chimeras J. Biol. Chem., September 15, 1995; 270(37): 21594 - 21599. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1990 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |